New activity is brewing for Avidity Biosciences ( (RNA) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
On January 30, 2026, Avidity Biosciences issued a definitive proxy statement convening a virtual special shareholders’ meeting for February 23, 2026 to vote on a proposed acquisition by Novartis AG and a related spin-off transaction. Under an October 25, 2025 merger agreement, Novartis’ Ajax Acquisition Sub would merge with Avidity, making Avidity an indirect wholly owned subsidiary of Novartis and converting each Avidity share into the right to receive $72 in cash, subject to shareholder approval by a majority of outstanding shares. In parallel, a separation and distribution agreement signed the same day would reorganize Avidity’s business so that a new subsidiary, Atrium Therapeutics (SpinCo), holds the company’s early-stage precision cardiology programs and certain collaborations, with those assets either distributed pro rata as SpinCo shares to Avidity shareholders (one SpinCo share for every ten Avidity shares) or potentially sold to a third party, with net cash proceeds distributed to shareholders and equity award holders. The board unanimously endorsed the merger and spin-off package, recommended shareholders vote in favor of the transactions and related proposals, and outlined appraisal rights for investors who oppose the deal, underscoring that completion of both the merger and spin-off hinges on shareholder approval at the February meeting.
The most recent analyst rating on (RNA) stock is a Hold with a $72.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.
Spark’s Take on RNA Stock
According to Spark, TipRanks’ AI Analyst, RNA is a Neutral.
The overall stock score reflects a mix of strong technical momentum and positive corporate events, particularly the merger with Novartis, which is a major strategic development. However, financial performance challenges, including negative profitability and cash flow, weigh on the score. The valuation reflects typical biotech growth characteristics, with a focus on future potential rather than current earnings.
To see Spark’s full report on RNA stock, click here.
More about Avidity Biosciences
Avidity Biosciences, Inc., based in San Diego, is a biotechnology company developing RNA-based therapies, including programs in early-stage precision cardiology targeting rare genetic cardiomyopathies such as phospholamban-related disease and Protein Kinase AMP-activated non-catalytic subunit Gamma 2 Syndrome. The company also maintains collaboration agreements with large pharmaceutical partners including Bristol-Myers Squibb and Eli Lilly, and operates within the broader biopharmaceutical sector focused on rare and serious diseases.
Average Trading Volume: 2,736,444
Technical Sentiment Signal: Buy
Current Market Cap: $10.92B
Find detailed analytics on RNA stock on TipRanks’ Stock Analysis page.